—
C+
C+ The full Closelook — membership. Open the C+ overview

Zoetis Inc (ZTS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Zoetis Inc

ZTS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Zoetis discovers, makes and sells medicines, vaccines, diagnostics and other health products for animals, covering pets such as dogs, cats and horses as well as livestock like cattle, swine and poultry. Its range spans parasite treatments, vaccines, pain and infection drugs, diagnostic instruments and tests, and precision tools for farm management. It sells through veterinarians, livestock producers and pet owners worldwide, and is based in Parsippany, New Jersey.
Where it sits in the stack
Zoetis carries no seat in Rubin or Halo, the diary's build-out indices, and sits outside the AI stack our diary tracks. It belongs to the healthcare sector, within animal-health drugs and diagnostics, a sleeve the diary follows separately from the semiconductor and data-centre build-out.
Who it is priced against
The diary holds no peer group for Zoetis; the comparison the market draws is with Elanco Animal Health, the other large listed animal-health maker.
Why Closelook tracks it
Zoetis holds a seat in the S&P 500 among the indices the diary tracks, but none in Rubin or Halo. It carries no Closelook score, and the diary records no quotes or mentions of it in past editions.
What the diary watches
The diary watches whether Zoetis's shares stabilise after their fall from the year's high, since further weakness would keep the stock away from the diary's usual coverage.

Zoetis Inc (ZTS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ZTS, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by TD Cowen, 2026-08-25

The Street on this name

Analyst actions and the latest print for ZTS from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target TD Cowen — target 94 Target set to $94 (+21.8% to spot) 2026-08-25
  • Price target Stifel — target 80 from 85 Target cut to $80 from $85 (+4.3% to spot) 2026-08-20

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · United States · 5 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ZTS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 2.86%, quarterly · last 0.53 USD on 2026-07-20

Dividends and capital return

What ZTS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 2.09 USD per share · a 2.86% yield on the 2026-09-17 close 4 distributions, paid quarterly 2026-09-17
  • Change on the year +7.8% against the prior twelve months prior twelve months 1.94 USD per share
  • Last distribution 0.53 USD per share as the price series records it, within days of the ex-date 2026-07-20
  • By calendar year 2023: 0.38 USD (partial) · 2024: 1.73 USD · 2025: 2.01 USD · 2026: 1.59 USD to date first distribution recorded in the three-year window: 2023-10-31

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Zoetis Inc (ZTS)?

Zoetis Inc trades as ZTS on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is ZTS in a Closelook index?

Not currently — Zoetis Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does ZTS trade against its moving averages?

Downtrend stack: Trades -3.1% vs the 50-day and -27.5% vs the 200-day average, 50.6% below the 52-week high and +2.8% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Zoetis Inc do?

Zoetis discovers, makes and sells medicines, vaccines, diagnostics and other health products for animals, covering pets such as dogs, cats and horses as well as livestock like cattle, swine and poultry. Its range spans parasite treatments, vaccines, pain and infection drugs, diagnostic instruments and tests, and precision tools for farm management. It sells through veterinarians, livestock producers and pet owners worldwide, and is based in Parsippany, New Jersey. The diary holds no peer group for Zoetis; the comparison the market draws is with Elanco Animal Health, the other large listed animal-health maker.

Where does Zoetis Inc sit in the AI build-out?

Zoetis carries no seat in Rubin or Halo, the diary's build-out indices, and sits outside the AI stack our diary tracks. It belongs to the healthcare sector, within animal-health drugs and diagnostics, a sleeve the diary follows separately from the semiconductor and data-centre build-out. Zoetis holds a seat in the S&P 500 among the indices the diary tracks, but none in Rubin or Halo. It carries no Closelook score, and the diary records no quotes or mentions of it in past editions.

Does Zoetis Inc pay a dividend?

Zoetis Inc has paid 2.09 USD per share over the last twelve months, paid quarterly, a trailing yield of 2.86% on the 2026-09-17 close; the last distribution recorded in the price series was 0.53 USD on 2026-07-20. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Zoetis Inc recently?

The most recent analyst action on Zoetis Inc on the Closelook wire is a price target by TD Cowen on 2026-08-25 (target 94). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ZTS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.